Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials

Area of Science:

• Oncology
• Immunotherapy
• Translational Medicine

Background:

• Immune checkpoint inhibitors (ICIs) are a cornerstone therapy for non-small cell lung cancer (NSCLC).
• A significant efficacy-effectiveness gap exists between clinical trials and real-world patient outcomes.
• Underrepresentation of specific patient subgroups in trials may contribute to this gap.

Purpose of the Study:

• To review the evidence of ICI effectiveness in real-world NSCLC patients.
• To identify patient populations with potentially different responses to ICIs.
• To highlight the impact of clinical and molecular characteristics on ICI outcomes.

Main Methods:

• Systematic review of clinical data and real-world evidence.
• Analysis of outcomes in patient subgroups based on performance status, comorbidities, and molecular alterations.
• Synthesis of data on immune checkpoint inhibitors in non-small cell lung cancer.

Main Results:

• Evidence suggests varying ICI effectiveness across diverse patient populations.
• Patients with poor Eastern Cooperative Oncology Group performance status (ECOG PS) and active brain metastases (BMs) may have different outcomes.
• Molecular aberrations like EGFR mutations and ALK fusions influence ICI response.

Conclusions:

• Real-world effectiveness of ICIs in NSCLC is influenced by patient-specific factors.
• Further research is needed to optimize ICI therapy for underrepresented populations.
• Tailoring treatment based on clinical and molecular profiles is crucial for improving patient outcomes.